Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis

Research output: Contribution to journalReviewpeer-review

  1. Prevalence of biofilms in acute infections challenges a longstanding paradigm

    Research output: Contribution to journalJournal articlepeer-review

  2. Self-assessed health status and associated mortality in endocarditis: secondary findings from the POET trial

    Research output: Contribution to journalJournal articlepeer-review

  3. A double negative: culture-negative infective endocarditis

    Research output: Contribution to journalEditorialpeer-review

View graph of relations

Patients with infective endocarditis (IE) form a heterogeneous group by age, co-morbidities and severity ranging from stable patients to patients with life-threatening complications with need for intensive care. A large proportion need surgical intervention. In-hospital mortality is 15-20%. The concept of using hyperbaric oxygen therapy (HBOT) in other severe bacterial infections has been used for many decades supported by various preclinical and clinical studies. However, the availability and capacity of HBOT may be limited for clinical practice and we still lack well-designed studies documenting clinical efficacy. In the present review we highlight the potential beneficial aspects of adjunctive HBOT in patients with IE. Based on the pathogenesis and pathophysiological conditions of IE, we here summarize some of the important mechanisms and effects by HBOT in relation to infection and inflammation in general. In details, we elaborate on the aspects and impact of HBOT in relation to the host response, tissue hypoxia, biofilm, antibiotics and pathogens. Two preclinical (animal) studies have shown beneficial effect of HBOT in IE, but so far, no clinical study has evaluated the feasibility of HBOT in IE. New therapeutic options in IE are much needed and adjunctive HBOT might be a therapeutic option in certain IE patients to decrease morbidity and mortality and improve the long-term outcome of this severe disease.

Original languageEnglish
Article number805964
JournalFrontiers in cellular and infection microbiology
Volume12
Pages (from-to)805964
ISSN2235-2988
DOIs
Publication statusPublished - 3 Feb 2022

Bibliographical note

Copyright © 2022 Lerche, Schwartz, Pries-Heje, Fosbøl, Iversen, Jensen, Høiby, Hyldegaard, Bundgaard and Moser.

ID: 74725118